The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Kobiakov G.L.

GBU NII neĭrokhirurgii im. N.N. Burdenko

Absaliamova O.V.

FGBU "Nauchno-issledovatel'skiĭ institut neĭrokhirurgii im. akad. N.N. Burdenko"

Poddubskiy A.A.

Burdenko Neurosurgical Institute, Moscow, Russia

Lodygina K.S.

Burdenko Neurosurgical Institute, Moscow, Russia

Kobyakova E.A.

Blokhin Russian Cancer Research Center, Kashirskoe Shosse, 23, Moscow, Russia, 115478

The 2016 WHO classification of primary central nervous system tumors: a clinician’s view

Authors:

Kobiakov G.L., Absaliamova O.V., Poddubskiy A.A., Lodygina K.S., Kobyakova E.A.

More about the authors

Journal: Burdenko's Journal of Neurosurgery. 2018;82(3): 88‑96

DOI: 10.17116/neiro201882388

Read: 20436 times

Download PDF (RU)
Download PDF
Contact the author
Table of contents

THE 2016 WHO CLASSIFICATION OF PRIMARY CENTRAL NERVOUS SYSTEM TUMORS: A CLINICIAN’S VIEW
THE 2016 WHO CLASSIFICATION OF PRIMARY CENTRAL NERVOUS SYSTEM TUMORS: A CLINICIAN’S VIEW

To cite this article:

Kobiakov GL, Absaliamova OV, Poddubskiy AA, Lodygina KS, Kobyakova EA. The 2016 WHO classification of primary central nervous system tumors: a clinician’s view. Burdenko's Journal of Neurosurgery. 2018;82(3):88‑96. (In Russ., In Engl.)
https://doi.org/10.17116/neiro201882388

Подписка 2025 Журнал «Вопросы нейрохирургии» имени Н.Н. Бурденко (Burdenko's Journal of Neurosurgery)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Glymphatic system in health and disease: a narrative review. Burdenko's Journal of Neurosurgery. 2025;(4):112-118
TERTp muta­tion screening using digi­tal droplet PCR of collection of 52 paired DNA samples from blood plasma and tumor tissue in patients with glioblastoma. Burdenko's Journal of Neurosurgery. 2025;(5):87-95
Fluorescence navi­gation and endo­scopic assi­stance in surgery for brain glioblastomas. Burdenko's Journal of Neurosurgery. 2025;(6):28-37
The choice of radiotherapy dose fractionation regi­men for grade 4 gliomas depe­nding on the status of MGMT. P.A. Herzen Journal of Onco­logy. 2025;(1):13-18
On the issue of classification of vomer defo­rmities in children. Russian Bulletin of Otorhinolaryngology. 2025;(1):35-42
Radiation therapy with focal dose esca­lation in the treatment of glioblastoma. P.A. Herzen Journal of Onco­logy. 2025;(2):64-69
Central audi­tory processing diso­rders: problems of defi­nition and classification. Russian Bulletin of Otorhinolaryngology. 2025;(2):4-8
On correct clinical and pathogenetic OCT-based classification of vitreomacular inte­rface pathologies. Russian Annals of Ophthalmology. 2025;(2):16-21
Machine learning models for brain tumors differential diagnosis. Russian Journal of Preventive Medi­cine. 2025;(9):87-93
The Duchenne muscular dystrophy continuum: a modi­fied staging classification. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(9):60-70
Abstract:

This article is devoted to the latest edition of the 2016 WHO classification of primary CNS tumors. The authors, who are clinicians and not morphologists, have tried to analyze and briefly present the main changes to the new edition of the WHO classification of primary CNS tumors, the main difference of which from the previous 2007 classification is inclusion of the molecular genetic features of primary CNS tumors in the classification criteria. The article focuses mainly on the classification issues of diffuse gliomas and glioblastoma, with assessment of the role of IDH-1,2, ATRX, TERT, and MGMT mutations as well as a 1p/19q co-deletion. The article briefly describes some new nosological forms (e.g., Grade III anaplastic pleomorphic xanthoastrocytoma) and presents a new approach to the classification of embryonic (medulloblastoma) and glial childhood tumors as well as tables of the main differences between 2016 and 2007 WHO classifications of primary CNS tumors. Based on their own clinical experience, the authors dispute with the described classification and suggest their own ideas for improving the classification of primary CNS tumors in the future.

Keywords:

CNS tumors
classification
glioma
glioblastoma
medulloblastoma
IDH
MGMT
1p/19q

Authors:

Kobiakov G.L.

GBU NII neĭrokhirurgii im. N.N. Burdenko

Absaliamova O.V.

FGBU "Nauchno-issledovatel'skiĭ institut neĭrokhirurgii im. akad. N.N. Burdenko"

Poddubskiy A.A.

Burdenko Neurosurgical Institute, Moscow, Russia

Lodygina K.S.

Burdenko Neurosurgical Institute, Moscow, Russia

Kobyakova E.A.

Blokhin Russian Cancer Research Center, Kashirskoe Shosse, 23, Moscow, Russia, 115478

Close metadata

References:

  1. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK. WHO Classification of Tumours of the Central Nervous System, Revised. 4th Ed. IARC (Lyon). 2016;408.
  2. Scheithauer BW. Development of the WHO Classification of Tumors of the Central Nervous System: A Historical Perspective. Brain Pathology. 2008 Sept;19:Issue 4:551-564. https://doi.org/10.1111/j.1750-3639.2008.00192
  3. Zülch KJ. Histological typing of tumours of the central nervous system. World Health Organization (Geneva). 1979.
  4. Kleihues P, Burger PC, Scheithauer BW. Histological Typing of Tumours of the Central Nervous System. World Health Organization. 1993. https://doi.org/10.1007/978-3-642-84988-6
  5. Kleihues P, Cavenee WK. (eds.). World Health Organisation classification of tumours: Pathology and genetics of tumours of the nervous system. IARC Press (Lyon). 2000.
  6. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK. (eds). World Health Organization Classification of Tumours of the Central Nervous System. IARC (Lyon). 2007.
  7. Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathologica. 2016;131:803-820. https://doi.org/10.1007/s00401-016-1545-1
  8. American Cancer Society (1968) Mannual Tumor Nomenclature and Coding. American Cancer Society: New York. 1968.
  9. Percy С, Fritz А, Jack А, Shanmugarathan S, Sobin L, Parkin DM, Whelan S. International Classification of Diseases for Oncology (ICD-O). 3rd edn. World Health Organization: Geneva. 2000.
  10. Zulch KJ. Brain Tumors: Their Biology and Pathology. 2nd edn. Springer Publishing Co. Inc.: New York. 1965.
  11. Kernohan JW, Sayre GP. Tumors of the Central Nervous System. Armed Forces Institute of Pathology: Washington, DC, 1952.
  12. Daumas-Duport C, Scheithauer B, O’Fallon J, Kelly P. Grading of astrocytomas. A simple and reproducible method. Cancer. 1988 Nov 15;62(10):2152-2165. PMID: 3179928
  13. Macko DE, Macko MV, Imyanitov EN. Neurooncology. Practical oncology. 2017;18(1):103-114. (In Russ.)
  14. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ, Friedman H, Friedman A, Reardon D, Herndon J, Kinzler KW, Velculescu VE, Vogelstein B, Bigner DD. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009 Feb 19;360(8):765-773. https://doi.org/10.1056/NEJMoa0808710
  15. Kazarova MV. Rol’ prognosticheskih factorov v vybore variantov posleoperacionnoi terapii pri kombinirovannom i kompleksnom lechenii pervichnyh anaplasticheskih gliom golovnogo mozga: Dis... kand.med.nauk. Moscow. 2016. (In Russ.)
  16. Chen L, Voronovich Z, Clark K, Hands I, Mannas J, Walsh M, Nikiforova MN, Durbin EB, Weiss H, Horbinski C. Predicting the likelihood of an isocitrate dehydrogenase 1 or 2 mutation in diagnoses of infiltrative glioma. Neurooncology. 2014;16:1478-1483. https://doi.org/10.1093/neuonc/nou097
  17. Olar A, Wani KM, Alfaro-Munoz KD, Heathcock LE, van Thuijl HF, Gilbert MR, Armstrong TS, Sulman EP, Cahill DP, VeraBolanos E. IDH mutation status and role of WHO grade and mitotic index in overall survival in Grade II—III diffuse gliomas. Acta Neuropathol. 2015;129:585-596. https://doi.org/10.1007/s00401-015-1398-z
  18. Reuss DE, Mamatjan Y, Schrimpf D, Capper D, Hovestadt V, Kratz A, Sahm F, Koelsche C, Korshunov A, Olar A, Hartmann C, Reijneveld JC, Wesseling P, Unterberg A, Platten M, Wick W, Herold-Mende C, Aldape K, von Deimling A. Acta Neuropathol 1 3 IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: a grading problem for WHO. Acta Neuropathol. 2015;129:867-873. https://doi.org/10.1007/s00401-015-1438-8
  19. Cairncross G, Jenkins R. Gliomas with 1p/19q codeletion: a.k.a. oligodendroglioma. Cancer J. 2008 Nov-Dec;14(6):352-357. https://doi.org/10.1097/PPO.0b013e31818d8178
  20. Absalyamova OV, Korshunov AG, Kobiakov GL, Golanov AV, Urakov SV, Amanov RD, Lichinitser MR. Influence of molecular-genetic factors on prognosis in patients with oligodendroglial tumors. Problems of Neurosurgery named after N.N. Burdenko. 2009;1:17-24. (In Russ.)
  21. Absalyamova OV. Clinical value of the genetic features of oligodendroglial tumors. First step of Russian PhD dissertation. Med Sci. GU “the Russian oncological scientific center, RAMS”. M. 2009. (In Russ.)
  22. Alentorn AM, Sanson IA. Oligodendrogliomas: new insights from the genetics and perspectives. Curr Opin Oncol. 2012;24:687-693. https://doi.org/10.1097/CCO.0b013e328357f4ea
  23. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. N Engl J Med. 2005 Mar 10;352(10):987-996. PMID: 15758009 https://doi.org/10.1056/NEJMoa043330
  24. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005 Mar 10;352(10):997-1003. PMID: 15758010 https://doi.org/10.1056/NEJMoa043331
  25. Broniscer A, Tatevossian RG, Sabin ND, Klimo PJr, Dalton J, Lee R, Gajjar A, Ellison DW. Clinical, radiological, histological and molecular characteristics of paediatric epithelioid glioblastoma. Neuropathol Appl Neurobiol. 2014;40:327-336. https://doi.org/10.1111/nan.12093
  26. Kleinschmidt-DeMasters BK, Aisner DL, Birks DK, Foreman NK. Epithelioid GBMs show a high percentage of BRAF V600E mutation. Am J Surg Pathol. 2013;37:685-698.https://doi.org/10.1097/PAS.0b013e31827f9c5e
  27. Hsiao SJ, Karajannis MA, Diolaiti D, Mansukhani MM, Bender JG, Kung AL, Garvin JHJr. A novel, potentially targetable TMEM106B-BRAF fusion in pleomorphic xanthoastrocytoma. Cold Spring Harb Mol Case Stud. 2017 March;3:a001396; Published in Advance. December 15, 2016. https://doi.org/10.1101/mcs.a001396
  28. Bechet D, Gielen GG, Korshunov A, Pfister SM, Rousso C, Faury D, Fiset PO, Benlimane N, Lewis PW, Lu C, David Allis C, Kieran MW, Ligon KL, Pietsch T, Ellezam B, Albrecht S, Jabado N. Specific detection of methionine 27 mutation in histone 3 variants (H3K27M) in fixed tissue from high-grade astrocytomas. Acta Neuropathol. 2014 Nov;128(5):733-741. https://doi.org/10.1007/s00401-014-1337-4
  29. Fuller CE, Jones DTW, Kieran MW. New Classification for Central Nervous System Tumors: Implications for Diagnosis and Therapy. Am Soc Clin Oncol Educ Book. 2017;37:753-763. https://doi.org/10.14694/edbk_175088
  30. Harter PN, Braun Y, Plate KH. Classification of meningiomas-advances and controversies. Chin Clin Oncol. 2017 Jun 4; pii: cco.2017.05.02. https://doi.org/10.21037/cco.2017.05.02
  31. Pietsch T, Haberler C. Update on the integrated histopathological and genetic classification of medulloblastoma — a practical diagnostic guideline. Clin Neuropathol. 2016 Nov/Dec;35(6):344-352. https://doi.org/10.5414/np300999
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.